Overview

This trial is active, not recruiting.

Condition osteoarthritis
Treatments sigma cr150, sigma cr
Phase phase 4
Sponsor DePuy International
Start date July 2011
End date June 2016
Trial size 200 participants
Trial identifier NCT01418378, CT07/04

Summary

This study will compare two very similar designs of knee replacement device. One device (Sigma CR150) is a slightly modified version of the original (Sigma CR) and has been modified to enhance/accommodate higher flexion. The original device has been in widespread clinical use with excellent results since 1996 and this study will determine whether the design modifications of the newer device add further value. The newer device has been in clinical use with good short-term(unpublished) outcomes since becoming commercially available in January 2009.

Achieving higher knee flexion may be required for cultural reasons or by the increasingly younger, more active patient population undergoing knee replacement today. In addition to promoting flexion, it is also possible that this design change may help the knee replacement to last longer than traditional implants in patients who achieve higher flexion. Therefore, the study will compare the two devices in terms of survivorship, flexion and other measures of the success of a total knee replacement (range of motion, knee-related quality of life, activity and generic quality of life) over the short-term.

A minimum of one hundred and forty subjects (minimum 70 per group) with osteoarthritis and aged 50-75 years will be included at UK/international hospitals.

Study duration is 2 years and patients will complete standard knee outcome scores plus radiological evaluation.

Subjects would receive one of the study devices regardless of their involvement in the study, and apart from (possible)additional visits, x-rays and/or questionnaires, treatment and follow-up care will be as per the care they would receive outside of the study.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking double blind (subject, outcomes assessor)
Primary purpose treatment
Arm
(Active Comparator)
Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
sigma cr150 PFC Sigma CR150
Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
(Active Comparator)
Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
sigma cr PFC Sigma CR
Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).

Primary Outcomes

Measure
Survivorship
time frame: 2 year

Secondary Outcomes

Measure
KOOS
time frame: 1 Year
Knee Society Score - Knee Evaluation
time frame: 1 Year
Radiographic evaluation
time frame: 1 Year
Comparative Flexion
time frame: 1 Year
Patient Satisfaction
time frame: 1 Year
Survivorship
time frame: 1 Year
KOOS
time frame: 2 Years
Knee Society Score - Knee Evaluation
time frame: 2 Years
Survivorship
time frame: 2 Year
Comparative Flexion
time frame: 2 Year
Radiographic evaluation
time frame: 2 Year

Eligibility Criteria

Male or female participants from 50 years up to 75 years old.

Inclusion Criteria

    Exclusion Criteria

      Additional Information

      Official title A Double-blinded Randomised Controlled Trial Comparing the Performance of the Sigma® CR150 and Sigma® CR Knee Systems, When Used in Fixed Bearing Primary Cruciate Retaining Total Knee Arthroplasty for the Treatment of Osteoarthritis
      Principal investigator Gautam Chakrabarty, FRCS Orth.
      Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
      Information provided to ClinicalTrials.gov by DePuy International.